Fungal infections are a growing concern in both hospital and community settings, particularly due to increasing resistance to conventional antifungal agents. Among the most resilient fungal contaminants is Aspergillus brasiliensis, an opportunistic mold frequently used in disinfectant validation studies. In this context, Ion Gel ZCM-25® has emerged as a breakthrough innovation, showcasing rapid antifungal efficacy supported by standardized testing and clinical relevance.
In 2020, the Laboratory of Immunological Specialties (LEI) in Mexico City evaluated the antifungal efficacy of Ion Gel ZCM-25® using a rigorous fungicidal challenge test. The results demonstrated not only high fungal kill rates but also significant clinical implications for infection control.
The test followed the Mexican Official Standard NMX-BB-040-SCFI-1999, which outlines procedures for evaluating antifungal efficacy in disinfectants and antiseptic products. This standard is aligned with global virucidal and fungicidal evaluation guidelines, ensuring that the data generated is relevant for real-world clinical applications.
Target microorganism: Aspergillus brasiliensis (ATCC 16404)
Method used: Quantitative suspension test
Study conducted by: M. en C. Israel Velázquez Martínez
Location: LEI Laboratory, Mexico City
The findings were unequivocal:
These results validate the antifungal efficacy of Ion Gel ZCM-25® under high microbial load and extremely short exposure time. Most commercial antifungal agents require several minutes to achieve this level of fungal reduction.
Aspergillus brasiliensis is a ubiquitous fungal pathogen with high environmental persistence and notable resistance to many conventional disinfectants. It is used as a benchmark organism in antifungal efficacy testing because of its known ability to survive on surfaces and medical equipment. In immunocompromised patients, Aspergillus species can cause invasive infections with high morbidity and mortality.
The ability of Ion Gel ZCM-25® to inactivate this organism in just 30 seconds without cytotoxic chemicals highlights its unique clinical utility. Unlike alcohol-based agents, which evaporate rapidly and dry the skin, Ion Gel ZCM-25® offers lasting protection and tolerance for frequent use.
The exceptional antifungal efficacy of Ion Gel ZCM-25® is attributed to its proprietary IBAL (Ion Biotechnology Aqueous Ligands) system. This redox-active ion matrix includes:
This unique combination attacks fungi on multiple biochemical fronts, making resistance less likely to develop.
Beyond its potent antifungal efficacy, Ion Gel ZCM-25® has demonstrated broad-spectrum antimicrobial action, including:
This positions the gel as a multifunctional topical therapy capable of addressing mixed infections commonly seen in chronic wounds and immunosuppressed patients.
Due to its validated antifungal efficacy, Ion Gel ZCM-25® can be used in various dermatological and wound care scenarios:
A key advantage of Ion Gel ZCM-25® lies not just in its antifungal efficacy, but in its outstanding tolerability:
This means it can be safely used on broken or sensitive skin—something most conventional antifungal creams or antiseptics cannot offer.
Traditional antifungal drugs target narrow biochemical pathways, leading to resistance and limited spectrum. In contrast, redox-active compounds like those in Ion Gel ZCM-25® exert physical and biochemical stress on multiple fungal targets simultaneously.
This multimodal mechanism enhances:
By targeting fungi holistically, redox therapies provide faster outcomes and reduce the chance of relapse, supporting a new generation of antifungal efficacy standards.
| Feature | Ion Gel ZCM-25® | Alcohol-Based Gel | Clotrimazole Cream |
|---|---|---|---|
| Antifungal efficacy | 99.95% in 30s | Variable | ~85% in 7 days |
| Onset of action | 30 seconds | Instant | Days |
| Spectrum | Broad-spectrum | Limited | Fungal only |
| Skin compatibility | Excellent | Drying | Moderate |
| Redox mechanism | Yes | No | No |
The confirmed antifungal efficacy of Ion Gel ZCM-25® against Aspergillus brasiliensis, backed by additional antibacterial and antiviral data, positions this gel as a next-generation topical therapeutic. Its rapid activity, broad spectrum, and excellent safety make it ideal for:
Its unique redox chemistry also aligns with current needs for non-antibiotic, non-resistance-inducing therapies.
Full antifungal challenge report:
https://zcm25.com/antifungal-disinfectant-activity-by-fungicide-challenge-aspergillus-brasiliensis
Scientific data and complementary antimicrobial studies:
https://zcm25.com/resources